EWG Elevate Inc. Takes $57,000 Position in Bristol-Myers Squibb (NYSE:BMY)

EWG Elevate Inc. acquired a new stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 791 shares of the biopharmaceutical company’s stock, valued at approximately $57,000.

A number of other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 199,886,585 shares of the biopharmaceutical company’s stock valued at $14,209,937,000 after purchasing an additional 3,058,491 shares in the last quarter. BlackRock Inc. boosted its position in Bristol-Myers Squibb by 2.0% during the 3rd quarter. BlackRock Inc. now owns 174,002,852 shares of the biopharmaceutical company’s stock valued at $12,369,862,000 after buying an additional 3,357,590 shares during the period. FMR LLC boosted its position in Bristol-Myers Squibb by 7.2% during the 2nd quarter. FMR LLC now owns 71,882,436 shares of the biopharmaceutical company’s stock valued at $5,534,947,000 after buying an additional 4,855,169 shares during the period. Northern Trust Corp boosted its position in Bristol-Myers Squibb by 1.9% during the 2nd quarter. Northern Trust Corp now owns 24,550,030 shares of the biopharmaceutical company’s stock valued at $1,890,352,000 after buying an additional 463,344 shares during the period. Finally, Legal & General Group Plc boosted its position in Bristol-Myers Squibb by 4.1% during the 2nd quarter. Legal & General Group Plc now owns 17,053,158 shares of the biopharmaceutical company’s stock valued at $1,313,101,000 after buying an additional 674,921 shares during the period. Hedge funds and other institutional investors own 75.51% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $66.53 on Friday. Bristol-Myers Squibb has a one year low of $65.28 and a one year high of $81.43. The company’s 50-day moving average is $70.96 and its 200 day moving average is $72.91. The company has a market capitalization of $139.63 billion, a price-to-earnings ratio of 22.55, a price-to-earnings-growth ratio of 1.47 and a beta of 0.46. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.14 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.71 by $0.11. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. The company had revenue of $11.41 billion for the quarter, compared to the consensus estimate of $11.20 billion. During the same period in the prior year, the firm posted $1.83 EPS. Bristol-Myers Squibb’s revenue for the quarter was down 4.8% on a year-over-year basis. Sell-side analysts expect that Bristol-Myers Squibb will post 8.07 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 1st. Investors of record on Monday, April 10th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 3.43%. The ex-dividend date of this dividend is Thursday, April 6th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 77.29%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, January 17th. They set an “overweight” rating and a $95.00 price target for the company. Atlantic Securities upped their price objective on shares of Bristol-Myers Squibb from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, February 3rd. Morgan Stanley upped their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “underweight” rating in a report on Friday, February 3rd. StockNews.com started coverage on shares of Bristol-Myers Squibb in a report on Thursday. They issued a “strong-buy” rating for the company. Finally, Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 3rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $79.69.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Ann Powell sold 11,183 shares of the firm’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the sale, the executive vice president now owns 23,043 shares of the company’s stock, valued at approximately $1,721,081.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Giovanni Caforio sold 240,000 shares of the firm’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the sale, the chief executive officer now owns 236,104 shares of the company’s stock, valued at approximately $17,625,163.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Ann Powell sold 11,183 shares of the firm’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the sale, the executive vice president now directly owns 23,043 shares in the company, valued at approximately $1,721,081.67. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.